SBR for Pharmaceutical Wastewater Treatment

Active pharmaceutical ingredient (API) and bulk drug manufacturing is run as campaign production — a reactor train is dedicated to one molecule's synthesis route for days or weeks, generating mother liquors, wash waters, and solvent recovery bottoms specific to that chemistry, before changing over to a different product with a different waste profile entirely. This batch production pattern is the starting point for treatment plant selection. A Sequencing Batch Reactor treats wastewater in discrete fill-react-settle-decant cycles within a single tank, which is structurally the same batch logic as the production process generating the waste. Continuous-flow systems, by contrast, assume a relatively steady influent quality and are retrofitted with large equalisation tanks to absorb pharma's campaign-to-campaign variability — SBR absorbs that variability natively in its cycle structure.

API wastewater chemistry is dominated by two characteristics that drive SBR design. First, COD typically runs 2,000–15,000 mg/L, set largely by residual reaction solvents (methanol, DMF, acetone, toluene) and unreacted process mother liquor rather than by simple organic load. Second, the BOD:COD ratio is low — typically 0.2 to 0.35 — because a large fraction of that COD comes from solvent residues and synthesis intermediates that are only partially biodegradable or essentially recalcitrant under aerobic conditions. A treatment system sized only to remove BOD will pass through most of the non-biodegradable COD untouched, which is why pharma SBR design always begins from the COD removal target, not the BOD target.

Toxicity to biomass is the second defining challenge. Antibiotics and many API intermediates are biologically active by design — several inhibit the same bacterial metabolic pathways an SBR depends on, at concentrations of single-digit mg/L. A conventional continuous activated sludge system exposes its entire suspended biomass inventory to whatever concentration arrives at that instant; a toxic batch can crash the whole system and take weeks to recover. SBR's batch structure allows incoming flow to be sampled, equalised in a holding tank, and fed into the reactor only after dilution or characterisation, and an acclimatized culture specific to a given plant's actual waste stream can be built and maintained in the tank over months of stable operation rather than starting from a generic seed each time.

Many bulk drug synthesis routes use amine intermediates or ammonium salts, producing wastewater with ammonical nitrogen well above 100 mg/L. SBR's cycle is naturally suited to nitrification-denitrification because aerobic and anoxic conditions are created in the same tank simply by switching aeration on and off — there is no need for a physically separate anoxic zone sized to a fixed flow rate. Cycle time allocation (aerobic react time for nitrification, anoxic react time for denitrification) is reconfigured per campaign as the ammonical nitrogen load changes, which gives pharma SBR plants a flexibility that fixed-geometry continuous nitrification-denitrification trains do not have.

CPCB classifies bulk drug and pharmaceutical units as red-category industry, and the applicable discharge standard for inland surface water is COD below 250 mg/L and BOD below 30 mg/L, tightened further by several State Pollution Control Boards within designated pharma cluster zones in Telangana, Andhra Pradesh, Gujarat, and Himachal Pradesh. Because biological treatment, including SBR, cannot remove fully non-biodegradable solvent-derived COD, most pharma SBR installations at the lower end of the BOD:COD range need a polishing step — powdered activated carbon (PAC) dosing within the cycle or post-SBR ozonation — to consistently bring residual COD under the discharge limit across changing campaigns rather than only on average.

Spans Envirotech designs SBR systems for bulk drug and API manufacturing with cycle programming built around each client's actual campaign schedule rather than a generic municipal-style cycle. Our design process includes BOD:COD and respirometric toxicity testing of representative composite samples across a full campaign, PAC or ozonation polishing sizing where the biodegradable fraction is insufficient, and PLC-based cycle control that lets plant operators reprogram aeration, anoxic, and react phase durations as the product mix changes — without civil modification to the tank.